stella
beta
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. โ Stella
Recruiting
Back to First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer trials
Phase 3 โ Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations
(1 site)
China
Clinical Trials Information Group, Beijing, chaoyang
View full record on ClinicalTrials.gov